Spark Therapeutics (NASDAQ: ONCE) announced positive top-line results from the Phase 3 pivotal trial of its lead gene therapy product ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments

Roth Capital Raises Price Target on Spark Therapeutics (ONCE) to $90 Following Top-Line Results October 5, 2015 11:03 AM Cowen Remains Bullish on Spark Therapeutics (ONCE) Following Top-Line SPK-RPE65 Results October 5, 2015 10:14 AM Spark Therapeutics Announces Positive Top-line Results From Pivotal Phase 3 Trial of SPK-RPE65 for Genetic Blinding ConditionsOctober 5, 2015 6:00 AM